While responses were not different between bamlanivimab- treated individuals and those who received placebo, CCL2, CCL19, CCL20, CXCL8 and CXCL10 were upregulated in samples from the nasopharyngeal cavity and the circulating blood of patients with COVID-19. This evidence concerns the gene CCL19 and COVID-19.